



Innovations in Nanomedicine for Disease Management

Guest Editors:

Dr. Anna Valentino

Research Institute on Terrestrial
Ecosystems (IRET)—CNR, Via
Pietro Castellino 111, 80131
Naples, Italy

Dr. Raffaele Conte

Research Institute on Terrestrial
Ecosystems (IRET)—CNR, Via
Pietro Castellino, 80131 Naples,
Italy

Deadline for manuscript
submissions:

closed (28 February 2026)

Message from the Guest Editors

Nanomedicine represents a revolutionary frontier in disease management, leveraging the unique properties of nanoparticles to transform diagnostics, therapeutics and drug delivery systems. This Special Issue delves into cutting-edge advancements in nanotechnology that offer precise, targeted and efficient solutions for a broad spectrum of medical challenges. "Innovations in Nanomedicine for Disease Management" explores the applications of nanomedicine in early disease detection, personalized medicine and minimally invasive treatments. It covers breakthroughs in smart drug delivery systems, optimizing therapeutic outcomes while minimizing side effects. Additionally, this Special Issue highlights the integration of nanotechnology with emerging fields such as gene therapy, immunotherapy, and regenerative medicine, aiming to underscore the transformative potential of nanomedicine in enhancing patient care and revolutionizing contemporary healthcare practices. Researchers and practitioners are invited to contribute to these groundbreaking studies that pave the way for the next generation of disease management technologies.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and
Center for Clinical Research
Learning, Spaulding
Rehabilitation Hospital and
Massachusetts General Hospital,
Harvard Medical School, Boston,
MA 02114, USA
2. Department of Epidemiology,
Harvard T.H. Chan School of
Public Health, Boston, MA 02115,
USA

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within *Scopus*, *SCIE (Web of Science)*, *PubMed*, *PMC*, *CAPus / SciFinder*, and other databases.

Journal Rank: JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Contact Us

Biomedicines Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/biomedicines
biomedicines@mdpi.com
[X@Biomed_MDPI](https://twitter.com/Biomed_MDPI)